Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for Octreotide long-acting depot injections

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline May 31, 2028 · 642 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Octreotid (ATC-Code nach WHO: H01CB02)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed purchase volumes; actual demand depends on physician prescribing behavior, patient numbers, and pharmacy...

The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, which typically oc...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive rebate agreement for Octreotide (ATC H01CB02) long-acting depot injections
  • Open-house model with continuous participation until 31 May 2028
Afficher le résumé complet

This is an Open-House model for non-exclusive rebate agreements under §130a(8) SGB V for Octreotide (ATC H01CB02) long-acting depot injections. The buyer is AOK PLUS. There is no guaranteed volume, no estimated value, and no exclusivity. The procedure is open to all qualified pharmaceutical companies continuously until 31 May 2028, with the first submission deadline on 30 April 2026. The notice explicitly states it is not a public procurement under EU directive.

Risques

No guaranteed purchase volumes; actual demand depends on physician prescribing behavior, patient numbers, and pharmacy...

The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, which typically oc...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company under §4(18) AMG for the offered product

Eligibility

  • Declaration of no exclusion grounds (§§123,124 GWB)

Administrative

  • Declaration regarding Russia sanctions (EU Regulation 833/2014)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; open-house model allows any eligible company to participate.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for Octreotide long-acting depot injections

Open-house model for non-exclusive rebate agreements on Octreotide (ATC H01CB02) limited to long-acting depot forms for injection. No minimum quantities, no exclusivity, continuous participation until 31 May 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; open-house model allows any eligible company to participate.

Date limite

Deadline May 31, 2028

Détails de la procédure

Date de publication
29 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
214696-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30